Pharmaceuticals Hong Kong

Hong Kong GLP-1 Receptor Agonists Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Hong Kong GLP-1 Receptor Agonists Market Industry Trends and Forecast to 2034: Segmented by (Drug, Route of Administration, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Hong Kong · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $81.2 Mn Placeholder estimate
Estimate 2025 $96.0 Mn 0.2% of the global market
Projected 2034 $435.7 Mn 353.8% Adds $339.7 Mn over 9 forecast years
CAGR 2025–2034 18.3% Faster than 81% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Hong Kong is 0.18% of the global market.
  • In APAC, the largest is China at $3.75 Bn.
  • Fastest growing: India at 20.6% a year.
  • Hong Kong ranks 7th of 10 by size in APAC.

Market size projection

Hong Kong

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$339.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
GLP-1 Receptor Agonists Market market size by year, Hong Kong
YearMarket sizeChange that yearSince 2025
2024 (estimate) $81.2 Mn — —
2025 (base) $96.0 Mn +$14.9 Mn —
2026 (forecast) $113.6 Mn +$17.6 Mn +18.3%
2027 (forecast) $134.4 Mn +$20.8 Mn +39.9%
2028 (forecast) $158.9 Mn +$24.6 Mn +65.6%
2029 (forecast) $188.0 Mn +$29.1 Mn +95.9%
2030 (forecast) $222.4 Mn +$34.4 Mn +131.7%
2031 (forecast) $263.1 Mn +$40.7 Mn +174.1%
2032 (forecast) $311.3 Mn +$48.2 Mn +224.3%
2033 (forecast) $368.3 Mn +$57.0 Mn +283.6%
2034 (forecast) $435.7 Mn +$67.4 Mn +353.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Hong Kong GLP-1 Receptor Agonists Market Analysis at a glance
Market size, 2025$96.0 Mn placeholder estimate
Forecast, 2034$435.7 Mn placeholder estimate
Growth (CAGR), 2025–203418.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug, route of administration, application and end user (see all)
Key playersNovo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and 1 more (see all)
Regulator in Hong KongDrug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026.
Active clinical trials1 in Hong KongSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Hong Kong GLP-1 Receptor Agonists Market Analysis Executive Summary

GLP-1 receptor agonists are medicines that mimic a gut hormone to lower blood sugar, slow digestion and reduce appetite. They are used to treat type 2 diabetes and obesity.

Key segments of the GLP-1 Receptor Agonists market include drug (Semaglutide, Tirzepatide and Liraglutide), route of administration (Injectable and Oral) and application (Type 2 Diabetes, Obesity and Cardiovascular Risk Reduction).

Bar chart: Hong Kong GLP-1 Receptor Agonists market size, 2024–2034, placeholder estimates. $81.2 Mn in 2024, $96.0 Mn in 2025 and $435.7 Mn in 2034, 18.3% CAGR.
Hong Kong GLP-1 Receptor Agonists market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Hong Kong GLP-1 Receptor Agonists Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the GLP-1 Receptor Agonists market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the GLP-1 Receptor Agonists market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for GLP-1 Receptor Agonists Market in Hong Kong

The GLP-1 Receptor Agonists market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for GLP-1 Receptor Agonists Market in Hong Kong

GLP-1 Receptor Agonists in Hong Kong: rules, payment and research

Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.⁠[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.⁠[2] ClinicalTrials.gov lists 1 study on GLP-1 Receptor Agonists that is recruiting, active or about to start in Hong Kong.⁠[3]

[1] Drug Office, Department of Health. Checked 14 Nov 2026.

[2] Hospital Authority. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for GLP-1 Receptor Agonists. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Hong Kong.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in GLP-1 Receptor Agonists right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

GLP-1 Receptor Agonists in context

Hong Kong compared

  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 16 countries we cover in APAC.[1]

[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the GLP-1 Receptor Agonists market in Hong Kong?
Placeholder estimate: about $96.0 Mn in 2025, rising to about $435.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the GLP-1 Receptor Agonists market in Hong Kong growing?
Placeholder estimate: about 18.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the GLP-1 Receptor Agonists market report cover?
The report splits the market by drug (Semaglutide, Tirzepatide, Liraglutide, Dulaglutide and more), route of administration (Injectable, Oral), application (Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the GLP-1 Receptor Agonists market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, Sanofi, Amgen Inc. and Pfizer Inc..
What is driving the GLP-1 Receptor Agonists market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the GLP-1 Receptor Agonists market.
Who regulates GLP-1 Receptor Agonists in Hong Kong?
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health. Source: Drug Office, Department of Health. Checked 14 Nov 2026.
How is healthcare paid for in Hong Kong?
Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government. Source: Hospital Authority. Checked 14 Nov 2026.
How many clinical trials on GLP-1 Receptor Agonists are running in Hong Kong?
1 study is recruiting, active or about to start in Hong Kong, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Hong Kong. Retrieved 12 Nov 2026.
How much research is published on GLP-1 Receptor Agonists?
PubMed lists 4,726 papers on GLP-1 Receptor Agonists added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Hong Kong

See all

Related on obesity and diabetes

See the topic